S&P 500   3,901.36 (+0.01%)
DOW   31,261.90 (+0.03%)
QQQ   288.46 (-0.39%)
AAPL   137.39 (+0.03%)
MSFT   252.66 (-0.19%)
FB   193.54 (+1.18%)
GOOGL   2,178.18 (-1.34%)
AMZN   2,154.20 (+0.36%)
TSLA   662.46 (-6.62%)
NVDA   167.39 (-2.25%)
BABA   86.80 (-1.01%)
NIO   16.50 (-0.96%)
AMD   93.61 (-3.17%)
CGC   5.52 (-5.96%)
MU   68.92 (-0.69%)
T   20.43 (+1.09%)
GE   75.30 (-0.58%)
F   12.45 (-3.11%)
DIS   102.25 (-0.86%)
AMC   12.03 (-8.03%)
PFE   52.47 (+3.59%)
PYPL   80.78 (-0.62%)
NFLX   186.35 (+1.56%)
S&P 500   3,901.36 (+0.01%)
DOW   31,261.90 (+0.03%)
QQQ   288.46 (-0.39%)
AAPL   137.39 (+0.03%)
MSFT   252.66 (-0.19%)
FB   193.54 (+1.18%)
GOOGL   2,178.18 (-1.34%)
AMZN   2,154.20 (+0.36%)
TSLA   662.46 (-6.62%)
NVDA   167.39 (-2.25%)
BABA   86.80 (-1.01%)
NIO   16.50 (-0.96%)
AMD   93.61 (-3.17%)
CGC   5.52 (-5.96%)
MU   68.92 (-0.69%)
T   20.43 (+1.09%)
GE   75.30 (-0.58%)
F   12.45 (-3.11%)
DIS   102.25 (-0.86%)
AMC   12.03 (-8.03%)
PFE   52.47 (+3.59%)
PYPL   80.78 (-0.62%)
NFLX   186.35 (+1.56%)
S&P 500   3,901.36 (+0.01%)
DOW   31,261.90 (+0.03%)
QQQ   288.46 (-0.39%)
AAPL   137.39 (+0.03%)
MSFT   252.66 (-0.19%)
FB   193.54 (+1.18%)
GOOGL   2,178.18 (-1.34%)
AMZN   2,154.20 (+0.36%)
TSLA   662.46 (-6.62%)
NVDA   167.39 (-2.25%)
BABA   86.80 (-1.01%)
NIO   16.50 (-0.96%)
AMD   93.61 (-3.17%)
CGC   5.52 (-5.96%)
MU   68.92 (-0.69%)
T   20.43 (+1.09%)
GE   75.30 (-0.58%)
F   12.45 (-3.11%)
DIS   102.25 (-0.86%)
AMC   12.03 (-8.03%)
PFE   52.47 (+3.59%)
PYPL   80.78 (-0.62%)
NFLX   186.35 (+1.56%)
S&P 500   3,901.36 (+0.01%)
DOW   31,261.90 (+0.03%)
QQQ   288.46 (-0.39%)
AAPL   137.39 (+0.03%)
MSFT   252.66 (-0.19%)
FB   193.54 (+1.18%)
GOOGL   2,178.18 (-1.34%)
AMZN   2,154.20 (+0.36%)
TSLA   662.46 (-6.62%)
NVDA   167.39 (-2.25%)
BABA   86.80 (-1.01%)
NIO   16.50 (-0.96%)
AMD   93.61 (-3.17%)
CGC   5.52 (-5.96%)
MU   68.92 (-0.69%)
T   20.43 (+1.09%)
GE   75.30 (-0.58%)
F   12.45 (-3.11%)
DIS   102.25 (-0.86%)
AMC   12.03 (-8.03%)
PFE   52.47 (+3.59%)
PYPL   80.78 (-0.62%)
NFLX   186.35 (+1.56%)
NASDAQ:CRNX

Crinetics Pharmaceuticals Price Target, Predictions & Analyst Ratings

$20.49
+0.69 (+3.48%)
(As of 05/20/2022 03:59 PM ET)
Add
Compare
Today's Range
$19.28
$20.56
50-Day Range
$16.49
$27.64
52-Week Range
$16.20
$28.95
Volume
13,710 shs
Average Volume
333,842 shs
Market Capitalization
$1.10 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.41

Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analyst Rating Consensus

Buy
Based on 7 Analyst Ratings

Analyst Price Target Consensus

$37.20
81.55% Upside

High PT$45.00
Average PT$37.20
Low PT$28.00
TypeCurrent
5/20/21 to 5/20/22
1 Month Ago
4/20/21 to 4/20/22
3 Months Ago
2/19/21 to 2/19/22
1 Year Ago
5/20/20 to 5/20/21
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
7 Buy rating(s)
7 Buy rating(s)
6 Buy rating(s)
4 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$37.20$37.20$36.80$36.75
Price Target Upside81.55% Upside65.35% Upside57.89% Upside131.28% Upside
Get Crinetics Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter.


Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Crinetics Pharmaceuticals (NASDAQ:CRNX) vs. Its Competitors

TypeCrinetics PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.72
2.52
Consensus RatingBuyBuyBuy
Price Target Upside86.37% Upside453.41% Upside29.02% Upside
News Sentiment RatingPositive News
Neutral News
Neutral News
MarketBeat
Community Rating
Outperform Votes
108
64.29%
Underperform Votes
60
35.71%
Avg. Outperform Votes
171
67.32%
Avg. Underperform Votes
83
32.68%
Avg. Outperform Votes
839
69.28%
Avg. Underperform Votes
372
30.72%

Crinetics Pharmaceuticals (NASDAQ:CRNX) Analyst Ratings History

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/6/2022JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Jonathan Wolleben
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$45.00+85.72%
3/31/2022Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Duncan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight
11/23/2021Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform
11/8/2021HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Price TargetBuy$30.00 ➝ $35.00+25.45%
9/16/2021Jonestrading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Soumit Roy
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$45.00+91.25%
6/18/2021JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Overweight$28.00+45.23%
5/31/2021SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$33.00+88.03%
12/23/2019Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Y. Rahimi
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$37.00+68.87%
(Data available from 5/20/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












Crinetics Pharmaceuticals (NASDAQ:CRNX) Analyst Ratings Frequently Asked Questions

What is Crinetics Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 7 analysts in the last year, the consensus rating for Crinetics Pharmaceuticals stock is Buy based on the current 7 buy ratings for CRNX. The average twelve-month price target for Crinetics Pharmaceuticals is $37.20 with a high price target of $45.00 and a low price target of $28.00. Learn more on CRNX's analyst rating history.

Do Wall Street analysts like Crinetics Pharmaceuticals more than its competitors?

Analysts like Crinetics Pharmaceuticals stock more than the stock of other Medical companies. The consensus rating score for Crinetics Pharmaceuticals is 3.00 while the average consensus rating score for medical companies is 2.72. Learn more on how CRNX compares to other companies.

Do MarketBeat users like Crinetics Pharmaceuticals more than its competitors?

MarketBeat users like Crinetics Pharmaceuticals stock less than the stock of other Medical companies. 64.29% of MarketBeat users gave Crinetics Pharmaceuticals an outperform vote while medical companies recieve an average of 67.32% outperform votes by MarketBeat users.

Does Crinetics Pharmaceuticals's stock price have much upside?

According to analysts, Crinetics Pharmaceuticals's stock has a predicted upside of 65.35% based on their 12-month price targets.

What analysts cover Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals has been rated by Cantor Fitzgerald, and JMP Securities in the past 90 days.

This page was last updated on 5/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.